One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023
René Westhovens ,1 Patrick Verschueren
doi : 10.1136/ard-2023-224904
December 2023 - Volume 82 - 12
Time to treat the climate and nature crisis as one indivisible global health emergency
Chris Zielinski, on behalf of the authorship group listed below
doi : 10.1136/ard-2023-225126
Potential for biosimilars in rheumatology in Africa
Mohamed Hassan Abu-Zaid ,1 Adewale Adebajo, 2,3 Yasser El Miedany
doi : 10.1136/ard-2023-224315
Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research
HanLin Xu ,1,2 Hengwei Qin ,1 YingHui Hua ,1 Nicola Dalbeth
doi : 10.1136/ard-2023-224679
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
Roy M Fleischmann ,1,2 Désirée van der Heijde ,3 Vibeke Strand ,4 Tatsuya Atsumi,5 Iain B McInnes,6 Tsutomu Takeuchi ,7,8 Peter C Taylor ,9 Marguerite Bracher,10 David Brooks, 11 John Davies, 10 Christopher Goode,12 Anubha Gupta, 10 Sumanta Mukherjee,11 Ciara O’Shea,13 Didier Saurigny,10 Lorrie A Schifano, 14 Celia Shelton,11 Julia E Smith,10 Millie Wang,12 Reena Wang,11 Sarah Watts, 10 Michael E Weinblatt
doi : 10.1136/ard-2023-224482
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Peter C Taylor ,1 Michael E Weinblatt,2 Iain B McInnes,3 Tatsuya Atsumi,4 Vibeke Strand ,5 Tsutomu Takeuchi ,6,7 Marguerite Bracher, 8 David Brooks,9 John Davies,10 Christopher Goode,10 Anubha Gupta,8 Sumanta Mukherjee,9 Ciara O’Shea,11 Didier Saurigny,8 Lorrie A Schifano,12 Celia Shelton,9 Julia E Smith,8 Millie Wang,10 Reena Wang,9 Sarah Watts,8 Roy M Fleischmann
doi : 10.1136/ard-2023-224449
Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis
Clément Triaille ,1,2 Gaëlle Tilman,2,3 Tatiana Sokolova,2 Axelle Loriot,4 Joelle Marchandise, 2 Stéphanie De Montjoye,5 Adrien Nzeusseu-Toukap ,5 Laurent Méric de Bellefon,5 Caroline Bouzin,6 Christine Galant,7 Patrick Durez ,2,5 Bernard R Lauwerys,2 Nisha Limaye
doi : 10.1136/ard-2023-224068
Directed differentiation of human pluripotent stem cells into articular cartilage reveals effects caused by absence of WISP3, the gene responsible for progressive pseudorheumatoid arthropathy of childhood
Chaochang Li,1 Mireia Alemany-Ribes,1 Rosanne M Raftery ,1 Uzochi Nwoko,1 Matthew L Warman,1,2 April M Craft
doi : 10.1136/ard-2023-224304
HLA-B27, axial spondyloarthritis and survival
Zhixiu Li ,1,2 Mohammad Kazim Khan ,3 Sjef M van der Linden ,4,5 Bjorn Winkens ,6 Peter M Villiger ,4,7 Heinz Baumberger,8 Hermine van Zandwijk ,9 Muhammad Asim Khan ,10 Matthew A Brown
doi : 10.1136/ard-2023-224434
Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
Kristina Elizabeth Neergaard Clark ,1 Shiwen Xu,1 Moustafa Attah,2 Voon H Ong,1 Christopher Dominic Buckley,2 Christopher P Denton
doi : 10.1136/ard-2023-224184
Benralizumab for eosinophilic granulomatosis with polyangiitis
Adrien Cottu ,1 Matthieu Groh ,2 Charlene Desaintjean,3 Sylvain Marchand-Adam, 4 Loïc Guillevin,1 Xavier Puechal ,1 Stacy Beaumesnil,5 Estibaliz Lazaro,5 Maxime Samson ,6 Camille Taille,7 Cécile- Audrey Durel,8 Elizabeth Diot,9 Sarah Nicolas,9 Laurent Guilleminault,10,11 Mikael Ebbo ,12 Pascal Cathebras,13 Clairelyne Dupin,14 Halil Yildiz, 15 Nabil Belfeki,16 Grégory Pugnet,17 Pierre Chauvin, 18 Stephane Jouneau,19 Francois Lifermann,20 Jean-Philippe Martellosio,21 Vincent Cottin ,3 Benjamin Terrier ,1,22 For the French Vasculitis Study Group
doi : 10.1136/ard-2023-224624
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study
Berengere Molina ,1 Roberto Padoan,2 Maria Letizia Urban,3 Pavel Novikov,4 Marco Caminati,5 Camille Taillé,6 Antoine Néel, 7 Laurence Bouillet,8,9 Paolo Fraticelli,10 Nicolas Schleinitz,11 Christine Christides,12 Laura Moi, 13 Bertrand Godeau,14 Ann Knight,15 Jan Walter Schroeder, 16 Sylvain Marchand- Adam,17 Helder Gil,18 Vincent Cottin ,19 Cécile- Audrey Durel,20 Elena Gelain,21 Boris Lerais,22 Marc Ruivard,23 Matthieu Groh ,24 Maxime Samson ,25,26 Luca Moroni,27 Jens Thiel,28,29 Anna Kernder,30 Jan Willem Cohen Tervaert,31,32 Giulia Costanzo,33 Marco Folci, 34 Sonia Rizzello, 35 Pascal Cohen,36 Giacomo Emmi ,3,37 Benjamin Terrier
doi : 10.1136/ard-2023-224756
Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism
Jose Manuel Mascaro,1,2,3 Ignasi Rodriguez-Pinto,4 Gabriela Poza,5 Anna Mensa-Vilaro,2,6 Julian Fernandez- Martin ,7 Luis Caminal-Montero,8,9 Gerard Espinosa
doi : 10.1136/ard-2023-224460
Evaluating the causal effect of circulating proteome on the risk of osteoarthritis-related traits
Yan Zhang ,1 Jingyu Xie,2 Simin Wen,3 Peihua Cao, 1 Wende Xiao,4 Jianwei Zhu,4 Shengfa Li, 1 Zhiqiang Wang ,1 Han Cen,1 Zhaohua Zhu ,1,5 Changhai Ding ,1,3 Guangfeng Ruan
doi : 10.1136/ard-2023-224459
Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
Edward Roddy ,1,2 Ram Bajpai, 1 Harry Forrester, 1 Richard James Partington ,1 Christian D Mallen,1 Lorna Elise Clarson ,1 Nishita Padmanabhan,1 Rebecca Whittle, 1 Sara Muller
doi : 10.1136/ard-2023-224154
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
Lisa Stamp ,1 Anne Horne,2 Borislav Mihov, 2 Jill Drake,3 Janine Haslett,1 Peter T Chapman,3 Christopher Frampton,1 Nicola Dalbeth
doi : 10.1136/ard-2023-224731
Finger ischaemia, enlarged spleen and lung nodules
Xavier Puéchal , Laure Delaval, Philippe Blanche
doi : 10.1136/ard-2023-224161
Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies
doi : 10.1136/ard-2023-224303
Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis
Yoon Y Qiu,1 Tuhina Neogi ,2 Lutfiyya N Muhammad,3 Jing Song, 3 Marcy B Bolster, 4 Wendy Marder, 5 Andrew C Heisler, 6 Alyssa Wohlfahrt,7 Dorothy Dunlop, 8 Yvonne C Lee
doi : 10.1136/ard-2023-224492
Correspondence on “Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry� by Machado et al
Rim Bourguiba ,1,2,3 Marion Delplanque,1,2,3 Léa Savey,1,2,3 Veronique Hentgen, 4 Gilles Grateau,1,2,3 Sophie Georgin-lavialle ,1,2,3,5 French national reference Center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial� by Molto et al
Uta Kiltz , Juergen Braun
Correspondence on ‘The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease’ by Wallace et al
G?zde Kübra Yard?mc? ,1,2 Beste Ekin Sandalc? Y?ld?r?m,3 Bayram Fariso?ullar?,1,2 Levent Kilic, 1,2 Omer Karadag
Correspondence on ‘NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus’ by Linge et al
George N Goulielmos ,1,2 Maria I Zervou,1 Elias Eliopoulos
